ALS-causing D169G Mutation Disrupts the ATP-binding Capacity of TDP-43 RRM1 Domain
Overview
Authors
Affiliations
TDP-43 inclusion is a pathological hallmark for ∼97% ALS and ∼45% FTD patients. So far, >50 ALS-causing mutations have been identified, most of which are hosted by the intrinsically-disordered prion-like domain. The D169G mutation is the only one within the well-folded RRM1 domain, which, however, induces no significant change of the crystal structure and even slightly enhances the thermodynamic stability. Therefore, the mechanism for D169G to enhance the cytotoxicity remains elusive. Here by NMR, we reveal for the first time: 1) D169G does trigger significant dynamic changes for a cluster of residues. 2) Very unexpectedly, D169G disrupts the ATP-binding capacity of RRM1 although the ATP-binding pocket is on the back side of the mutation site. Taken together with our previous results, the current study provides a potential mechanism to rationalize enhancement of the TDP-43 cytotoxicity by D169G and highlights again the key roles of ATP in neurodegenerative diseases and ageing.
The Regulation of TDP-43 Structure and Phase Transitions: A Review.
Liu Y, Xiang J, Gong H, Yu T, Gao M, Huang Y Protein J. 2025; .
PMID: 39987392 DOI: 10.1007/s10930-025-10261-0.
Decoding TDP-43: the molecular chameleon of neurodegenerative diseases.
Zeng J, Luo C, Jiang Y, Hu T, Lin B, Xie Y Acta Neuropathol Commun. 2024; 12(1):205.
PMID: 39736783 PMC: 11687198. DOI: 10.1186/s40478-024-01914-9.
Song J Int J Mol Sci. 2024; 25(23).
PMID: 39684527 PMC: 11641266. DOI: 10.3390/ijms252312817.
Song J Biomolecules. 2024; 14(4).
PMID: 38672516 PMC: 11048592. DOI: 10.3390/biom14040500.
Long way up: rethink diseases in light of phase separation and phase transition.
Ding M, Xu W, Pei G, Li P Protein Cell. 2023; 15(7):475-492.
PMID: 38069453 PMC: 11214837. DOI: 10.1093/procel/pwad057.